肺癌筛查的成本效果与预算影响:系统综述
全部预算影响分析均针对低剂量CT(LDCT)筛查项目,8项报告预算增加、1项相反。作者认为LDCT筛查在高危人群中总体具成本效果,但项目实施可能带来显著预算影响。
要点
- LDCT筛查在高危人群中总体具成本效果,但纳入研究间方法学差异大。
- 预算影响分析均针对LDCT筛查项目,多数显示预算增加。
- 人工智能、基因组学与生物标志物等新技术可能提升筛查效率,尚待经济学评价。
核心结论
- 综述提示LDCT筛查在高危人群中总体具成本效果,但实施肺癌筛查项目可能带来显著预算影响。
- 新兴技术、新疗法与联合筛查有潜力提高筛查效率,仍需未来经济学评价加以评估。
研究设计与样本
- 系统综述,检索六个数据库自建库至2025年7月31日。
- 纳入标准为对肺癌筛查进行完整经济学评价和/或预算影响分析(BIA)的文章。
- 完整经济学评价采用CHEQUE工具进行质量评估,BIA采用修改后的ISPOR指南作为质量清单。
- 采用叙述性综合汇总纳入研究。
主要发现
- 所有BIA均评估基于LDCT的筛查项目,8项发现预算增加,1项报告相反。
- 纳入研究在合格人群定义、建模方法、假定参与率、成本构成、效用值来源与公平性考量等方面存在显著方法学差异。
临床怎么用
- 在考虑开展肺癌筛查项目时,可参考本综述提示的LDCT在高危人群中的成本效果证据。
- 制定政策时需同时评估筛查项目对预算的影响,多数BIA显示预算增加。
局限性
- 纳入研究在合格人群定义、建模方法、参与率假设、成本构成、效用值来源与公平性考量等方面存在显著方法学差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pharmacoeconomics. 2026 Nov;44(11):1343-1367. doi: 10.1007/s40273-026-01639-8. Epub 2026 Jul 22. ABSTRACT INTRODUCTION: Clinical trials have demonstrated the benefits of early detection of lung cancer (LC); however, the implementation of national LC screening programs remains under consideration. Economic evaluations provide evidence-based insights to support informed policy decisions. OBJECTIVES: This systematic review aims to comprehensively synthesize the health economic evidence on LC screening and examine the methodological challenges. METHODS: We searched six databases from inception to July 31, 2025. Articles were included if evaluating LC screening using a full economic evaluation and/or budget impact analysis (BIA). The Criteria for Health Economic Quality Evaluation (CHEQUE) tool was used for quality assessment of full economic evaluations. The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) guidelines were modified as a quality checklist for BIA studies. Narrative synthesis was conducted to summarize the included studies. RESULTS: Ninety-five articles were identified, representing 93 full economic evaluations and nine BIAs. Seventy-nine full economic evaluations supported the cost-effectiveness of LC screening, while five indicated it was not cost-effective. Seventy studies evaluated low-dose computed tomography (LDCT) screening compared with no screening. Twelve studies considered emerging technologies either as standalone screening modalities or as adjuncts to LDCT screening, including artificial intelligence, genomics, and biomarkers. All BIAs assessed an LDCT-based screening program. Eight studies found that it would increase the budget, while one reported the opposite. All included studies demonstrated substantial methodological variation, including differences in the definition of eligible populations, modeling approaches, assumed uptake rates, cost components, sources of utility values, and equity consideration. CONCLUSION: Our review suggests that LDCT screening is generally cost-effective in high-risk populations, although implementing LC screening programs may entail a substantial budgetary impact. Emerging technologies, novel therapies, and combined screening have the potential to improve screening efficiency. Future economic evaluations are needed to assess these advances, while addressing existing methodological challenges to improve alignment between evidence. This review provides up-to-date economic evide
引用
- PubMed 高证据 · 肺结节与肺癌筛查:Cost-Effectiveness and Budget Impact of Lung Cancer Screening: A Systematic Review
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。